SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 9/30/2016 2:36:31 AM - Followers: 837 - Board type: Free - Posts Today: 9

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

 
Elite’s website can be found by going to http://www.elitepharma.com


How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.
 


 

Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79416&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78453&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=78262&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77581&GoTopage=1&Category=2163&BzID=2258&t=1948&G=939

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=77479&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0


More information can be found by going to Elite’s investor section:  http://ir.elitepharma.com/press_releases
Highlights From Last Quarter:
 
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
 
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
 
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.
 

Financials:
 
 
 

Products:
 
http://www.elitepharma.com/products/

Leadership:

President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.


Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: dianne@elitepharma.com

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755
 


Miscellaneous Links:

SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov: https://www.clinicaltrials.gov/




 


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.

               



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ELTP News: Current Report Filing (8-k) 09/01/2016 04:32:35 PM
ELTP News: Current Report Filing (8-k) 08/31/2016 04:19:33 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 08/19/2016 05:48:03 PM
ELTP News: Four Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements 07/27/2016 09:00:00 AM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/21/2016 11:47:37 AM
PostSubject
#226048  Sticky Note Elite Pharmaceuticals (ELTP) is NOT a Religion !! IB_ 09/05/16 12:28:35 PM
#226023  Sticky Note Concerning the Warning Letter for those interested in Minding 09/05/16 11:37:37 AM
#225095  Sticky Note THIS IS WHAT YOU NEED TO KNOW BEFORE Couch 08/31/16 08:53:18 AM
#222196  Sticky Note Freedom of Information Act Request to FDA WeeZuhl 08/17/16 07:21:46 AM
#217429  Sticky Note Here is the TRUTH about T-max-SEC-Filed! Drugdoctor 07/25/16 06:43:08 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#228617   KEEP an eye on PMD float is only stockboy 09/30/16 02:37:48 AM
#228616   They are not a big player and never stockboy 09/30/16 02:36:31 AM
#228615   Yet the FDA answer still the same. I warrentt 09/30/16 02:27:45 AM
#228614   I agreed completely. If you notice that over warrentt 09/30/16 02:25:19 AM
#228613   OTC can make money, but there is no stockboy 09/30/16 02:08:57 AM
#228612   Just like I was promised $2.00 on JuLY stockboy 09/30/16 02:07:46 AM
#228611   You mean .17 we're already below .18. stockboy 09/30/16 02:00:39 AM
#228610   This information was originally posted by frisko on Bluesummers 09/30/16 01:08:45 AM
#228609   Looking forward to great news coming next week. aELmTPa 09/30/16 12:26:20 AM
#228608   Big buyer creamed by bigger seller!!! This sends a namtae 09/29/16 10:11:00 PM
#228607   I sure hope we hold .18 tomorrow. lowandaway 09/29/16 10:02:46 PM
#228605   Tell me again what was the PPS Nasrat Couch 09/29/16 09:42:20 PM
#228604   That worked for nasRAT at over 30¢ and John_Langston 09/29/16 09:40:12 PM
#228603   Might actually want to start here: Couch 09/29/16 09:34:12 PM
#228602   This is a good place to start. John_Langston 09/29/16 09:31:02 PM
#228601   I like ELTP and give it that support. John_Langston 09/29/16 09:28:25 PM
#228600   I'm preferential to SEC filings myself. Couch 09/29/16 09:21:36 PM
#228599   17th most read board and nobody cares - Couch 09/29/16 09:20:22 PM
#228598   Gee that would be true if every word John_Langston 09/29/16 09:19:32 PM
#228597   Just like the trophy I've been waiting for Couch 09/29/16 09:18:59 PM
#228596   Look at the trade action; no one cares. lol John_Langston 09/29/16 09:18:21 PM
#228595   Whoot whoot I will get nasRAT a trophy John_Langston 09/29/16 09:17:18 PM
#228594   What??? John_Langston 09/29/16 09:12:46 PM
#228593   Gee that would be true if every word Couch 09/29/16 09:12:01 PM
#228592   LOL and the FDA is kicking his half John_Langston 09/29/16 09:10:13 PM
#228591   Sure thing - what was that first drug Couch 09/29/16 09:07:58 PM
#228590   It use to work for nasRAT but not John_Langston 09/29/16 09:04:33 PM
#228589   .068 on his first day aboard $$$$$$ Couch 09/29/16 09:03:21 PM
#228588   Soon - as in 5 plus years and Couch 09/29/16 09:02:41 PM
#228587   Like I said easily on the first ADT Couch 09/29/16 09:01:41 PM
#228586   For nasRAT? I knew that!!! John_Langston 09/29/16 09:01:25 PM
#228585   And that was on no ADTs on the Couch 09/29/16 09:00:41 PM
#228584   This epidemic is getting sad. Taking over our Bluesummers 09/29/16 09:00:39 PM
#228583   Sure thing!! PPS = .068 John_Langston 09/29/16 09:00:35 PM
#228582   What; shares over a dollar? lol lol lol John_Langston 09/29/16 08:58:36 PM
#228581   Just more total BS. John_Langston 09/29/16 08:57:25 PM
#228580   The Nasrat way - .068 on the day Couch 09/29/16 08:54:14 PM
#228579   5 plus years and still waiting for the Couch 09/29/16 08:53:10 PM
#228578   Gee that would be 100% true if it John_Langston 09/29/16 08:52:53 PM
#228577   Just like what happened to the $2 dollars John_Langston 09/29/16 08:49:59 PM
#228576   Well that explains the OTC companies with $30 Couch 09/29/16 08:47:02 PM
#228575   This is Elite. Couch 09/29/16 08:45:23 PM
#228574   As you can see all those revenues don't John_Langston 09/29/16 08:39:08 PM
#228573   Just more BS John_Langston 09/29/16 08:36:24 PM
#228572   Got it so nobody knows who it is. Next Couch 09/29/16 08:34:22 PM
#228571   Nope as I'm the one countering the BS. Couch 09/29/16 08:33:37 PM
#228570   LOL they were sold or dumped on the John_Langston 09/29/16 08:32:24 PM
#228569   Look at the PRs and CCs and then Couch 09/29/16 08:31:50 PM
#228568   So no BS now? LOL John_Langston 09/29/16 08:29:55 PM
#228567   That poor sap got nailed in one day; John_Langston 09/29/16 08:28:48 PM
PostSubject